Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660333 | 0.89 | CA2 (0.39) | CA2CHKAAAK1NPC1MEN1 | |
| SCHEMBL16532258 | 0.85 | CA2 (0.36) | CA2CHKAAAK1NPC1MEN1 | |
| SCHEMBL17663 | 0.82 | CA2 (0.56) | CA2CHKAAAK1NPC1MEN1 | |
| SCHEMBL29416323 | 0.82 | NPC1 (0.33) | CA2CHKANPC1MEN1KMT2A | |
| SCHEMBL1661897 | 0.82 | NPC1 (0.33) | CA2CHKANPC1MEN1KMT2A | |
| SCHEMBL16513728 | 0.80 | NPC1 (0.33) | CA2CHKANPC1MEN1KMT2A | |
| SCHEMBL16513403 | 0.80 | CA2 (0.39) | CA2CHKAMEN1KMT2A | |
| SCHEMBL24136814 | 0.78 | CA2 (0.38) | CA2CHKAMEN1KMT2A | |
| SCHEMBL1660874 | 0.78 | NPC1 (0.35) | NPC1MEN1KMT2A | |
| SCHEMBL12553865 | 0.77 | CA2 (0.40) | CA2CHKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | BIOGEN MA INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250304577-A1 | TYK2 INHIBITORS | BIOGEN MA INC. | 2025-10-02 | — | — | US | disclosed |
| US-20250195536-A1 | BICYCLOOCTANE KRAS INHIBITORS | INCYTE CORP (US) | 2025-06-19 | — | — | US | disclosed |
| WO-2025129002-A1 | BICYCLOOCTANE KRAS INHIBITORS | INCYTE CORPORATION (US) | 2025-06-19 | — | — | WO | disclosed |
| CN-119894879-A | Tyrosine kinase 2 inhibitors and uses thereof | 渤健马萨诸塞州股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-119654322-A | TYK2 inhibitors | 渤健马萨诸塞州股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | PROXIMAGEN LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| US-8796283-B2 | Indole and azaindole modulators of the alpha 7 nachr | PROXIMAGEN LIMITED (GB) | 2014-08-05 | — | — | US | disclosed |
| EP-2488514-B1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LTD (GB) | 2013-12-25 | — | — | EP | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (UK) | 2012-11-08 | — | — | US | disclosed |
| EP-2488514-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | Proximagen Limited (GB) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011045353-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | PROXIMAGEN LIMITED (GB) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150005321-A1 | Indole and azaindole modulators of the alpha 7 nAChR | CHRNA7, CHRNA5, CHRNA1 | CA2 1089/4885CHKA 195/4885AAK1 1929/4885 |
| US-20250304577-A1 | TYK2 INHIBITORS | TYK2, JAK2, JAK1 | CA2 2724/4885CHKA 567/4885AAK1 349/4885 |
| US-20250195536-A1 | BICYCLOOCTANE KRAS INHIBITORS | KRAS, NRAS, HRAS | CA2 2315/4885CHKA 905/4885AAK1 949/4885 |
| US-20120283273-A1 | INDOLE AND AZAINDOLE MODULATORS OF THE ALPHA 7 NACHR | CHRNA7, CHRNA5, CHRNA1 | CA2 1092/4885CHKA 200/4885AAK1 1876/4885 |
| US-20260028365-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | TYK2, ERBB2, ROS1 | CA2 683/4885CHKA 422/4885AAK1 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.